Sweet's Syndrome Rash: Clinical Features and Treatment
Sweet's syndrome is characterized by tender, red inflammatory nodules or papules, usually affecting the upper limbs, face, or neck, and systemic corticosteroids are the effective first-line treatment. 1
Clinical Features of the Rash
The rash in Sweet's syndrome presents with distinctive characteristics:
Morphology and Distribution
- Lesion types: Erythematous, edematous papules, nodules, or plaques that are characteristically tender and painful 1, 2
- Primary locations: Upper limbs, face, neck, and trunk 1, 2
- Less common sites: Can involve any body area, though truncal predominance may occur in atypical presentations 3
Associated Features
- Systemic symptoms: Fever is typical, though afebrile presentations can occur 3, 2
- Timing: Abrupt onset, often preceded by upper respiratory tract infection 4
- Pain: Marked tenderness is a prominent feature distinguishing it from other dermatoses 2, 5
- Laboratory findings: Neutrophilia and elevated inflammatory markers (ESR, CRP) are characteristic 2, 4
Distinguishing Features from Similar Conditions
Sweet's syndrome belongs to the acute neutrophilic dermatoses group but can be distinguished from related conditions 1:
- Versus Pyoderma Gangrenosum: Sweet's differs by its appearance, distribution, and lack of deep excavating ulcerations with purulent material 1
- Versus Erythema Nodosum: EN presents as subcutaneous nodules (1-5 cm) on extensor surfaces, particularly anterior tibial areas, rather than the papules/plaques of Sweet's on upper body 1
Histopathological Confirmation
Skin biopsy is crucial for diagnosis 2, 5:
- Dense neutrophilic infiltrate in the dermis without true vasculitis
- Leukocytoclasia may be present
- Absence of infectious organisms
- Direct immunofluorescence is negative 3
Treatment Approach
First-Line Therapy
Systemic corticosteroids remain the therapeutic gold standard 1, 4:
- Prompt and dramatic improvement of symptoms and skin lesions occurs after initiation 4
- Typical regimen: Prednisone 1 mg/kg daily with gradual taper 6
- Response is usually evident within days to one week 7
Alternative First-Line Agents
For patients unable to tolerate corticosteroids 4:
- Potassium iodide: Effective oral alternative
- Colchicine: Another first-line option
Second-Line Therapies
When corticosteroids fail or are contraindicated 4, 8:
- Indomethacin
- Dapsone
- Cyclosporine
- Clofazimine
Emerging Therapies
Recent evidence supports newer agents in refractory cases 7, 8:
- JAK inhibitors (e.g., upadacitinib): Demonstrated rapid control in anti-TNF refractory cases
- Biologic agents and small molecules show promise
Critical Clinical Considerations
Association with Underlying Disease
Always evaluate for associated conditions 1, 2, 4:
- Inflammatory bowel disease: Strong association, particularly with colonic involvement and active disease 1
- Malignancy: Approximately one-third of cases, most commonly acute myeloid leukemia 4
- Drug-induced: Most commonly granulocyte-colony stimulating factor 4
- Infectious triggers: Often preceded by upper respiratory infections 3, 4
Special Populations
- Women with colonic IBD: Strong predilection for this demographic 1
- Hematologic malignancies: Particularly AML patients, even during neutropenia from chemotherapy 9
- Pregnancy: Recognized association 4
Management Pitfalls to Avoid
Misdiagnosis as infection: The combination of fever, neutrophilia, and painful rash in immunocompromised patients (especially post-chemotherapy) is frequently mistaken for infection unresponsive to antimicrobials 9
Overlooking active underlying disease: In IBD patients, Sweet's syndrome may indicate active intestinal inflammation even when prior endoscopy suggested remission—re-assessment of bowel disease activity is crucial 7
Delayed biopsy: Histopathological confirmation prevents misdiagnosis and guides appropriate therapy 5
Inadequate workup: Failure to screen for malignancy, particularly in new-onset cases without obvious triggers 4